Journal of Neuro-Oncology

, Volume 142, Issue 2, pp 263–272 | Cite as

Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data

  • Xiu-Jian Ma
  • Da Li
  • Liang Wang
  • Shu-Yu Hao
  • Li-Wei Zhang
  • Jun-Ting Zhang
  • Zhen WuEmail author
Clinical Study



We aim to delineate the clinical characteristics of patients with primary intracranial solitary plasmacytoma (PISPC) and prognostic factors for their outcomes.


This study retrospectively reviewed 17 patients with PISPC from our center and an additional 70 cases of PISPC published previously to analyze outcome predictors.


The entire cohort included 38 (43.7%) males and 49 (56.3%) females with a mean age of 54 years. Skull base tumors were found in 49 (56.3%) patients. Gross total resection (GTR) was achieved in 31 (35.6%) patients. Postoperative adjuvant treatments, including radiotherapy (RT) alone, chemotherapy (CMT) alone, and RT + CMT were administered in 49 (56.3%) patients, 3 (3.5%) patients, and 16 (18.4%) patients, respectively. After a median follow-up of 24 (mean 42.4) months, the 5-year disease progression-free survival (PFS), recurrence-free survival (RFS), multiple myeloma (MM)-free survival (MMFS), and overall survival (OS) were 52.9%, 76.2%, 69.6%, and 76.1%, respectively. Multivariate analysis unveiled that a skull base tumor location (HR 2.395, p = 0.040) and no RT (HR 3.115, p = 0.004) were negative prognostic factors for PFS, no RT (HR 10.526, p = 0.003) for RFS, each 1-year increase in age (HR 1.039, p = 0.049) for MMFS, and increasing age (HR 1.052, p = 0.043) and CMT (HR 6.022, p = 0.005) were risk factors for OS. However, GTR did not benefit the aforementioned outcomes.


For patients with presumed PISPC, a biopsy followed by RT is recommended for skull base PISPC. However, the role of CMT is still not clear. Our findings need to be verified in a larger prospective cohort in the future. Systematic review registration number CRD42018098782.


Primary intracranial solitary plasmacytoma Multiple myeloma development Radiotherapy Chemotherapy 



Confidence interval




Gross total resection


Hazard ratio


Nongross total resection


Overall survival


Primary intracranial solitary plasmacytoma




Solitary plasmacytoma



This work was supported in part by the Natural Science Foundation of China (Grant No.81672506 to Z.W. and 814742370 to J.T.Z.).

Compliance with ethical standards

Conflict of interest

All the authors declared that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

11060_2019_3089_MOESM1_ESM.tif (7 mb)
Supplementary material 1 (TIF 7196 KB)
11060_2019_3089_MOESM2_ESM.docx (27 kb)
Supplementary material 2 (DOCX 27 KB)
11060_2019_3089_MOESM3_ESM.docx (20 kb)
Supplementary material 3 (DOCX 19 KB)
11060_2019_3089_MOESM4_ESM.docx (115 kb)
Supplementary material 4 (DOCX 114 KB)
11060_2019_3089_MOESM5_ESM.docx (19 kb)
Supplementary material 5 (DOCX 18 KB)
11060_2019_3089_MOESM6_ESM.docx (19 kb)
Supplementary material 6 (DOCX 19 KB)
11060_2019_3089_MOESM7_ESM.docx (21 kb)
Supplementary material 7 (DOCX 20 KB)
11060_2019_3089_MOESM8_ESM.docx (21 kb)
Supplementary material 8 (DOCX 20 KB)


  1. 1.
    Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D, Guidelines Working Group of the UKMF, British Committee for Standards in H, British Society for H (2004) Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 124 (6):717–726. CrossRefGoogle Scholar
  2. 2.
    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. CrossRefGoogle Scholar
  3. 3.
    Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ (2016) Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol 91(6):575–580. CrossRefGoogle Scholar
  4. 4.
    Schwartz TH, Rhiew R, Isaacson SR, Orazi A, Bruce JN (2001) Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study. Neurosurgery 49(5):1039Google Scholar
  5. 5.
    Mclaughlin DM, Gray WJ, Jones FG, Mirakhur M, Mccance DR, Sheridan B, Atkinson AB (2004) Plasmacytoma: an unusual cause of a pituitary mass lesion. A case report and a review of the literature. Pituitary 7(3):179–181CrossRefGoogle Scholar
  6. 6.
    Mandagere KA, Schimke RN, Kyner JL, Bhatia PS (1998) An unusual sellar mass–solitary plasmacytoma. Endoc Pract 4(6):382CrossRefGoogle Scholar
  7. 7.
    Pritchard PB 3rd, Martinez RA, Hungerford GD, Powers JM, Perot PL Jr (1983) Dural plasmacytoma. Neurosurgery 12(5):576–579CrossRefGoogle Scholar
  8. 8.
    Bindal AK, Bindal RK, van Loveren H, Sawaya R (1995) Management of intracranial plasmacytoma. J Neurosurg 83(2):218–221. CrossRefGoogle Scholar
  9. 9.
    Gagliardi F, Losa M, Boari N, Spina A, Reni M, Terreni MR, Mortini P (2013) Solitary clival plasmocytomas: misleading clinical and radiological features of a rare pathology with a specific biological behaviour. Acta Neurochir 155(10):1849–1856. CrossRefGoogle Scholar
  10. 10.
    Lee J, Kulubya E, Pressman BD, Mamelak A, Bannykh S, Zada G, Cooper O (2017) Sellar and clival plasmacytomas: case series of 5 patients with systematic review of 65 published cases. Pituitary 20(3):381–392. CrossRefGoogle Scholar
  11. 11.
    Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, Patriarca F, Nozzoli C, Cavo M, Offidani M, Floridia M, Berretta S, Vallone R, Musto P, Lauria F, Party GMW, Marchini E, Fabbri A, Oliva S, Zamagni E, Sapienza FG, Ballanti S, Mele G, Galli M, Pirrotta MT, Di Raimondo F (2012) Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer 118(6):1574–1584. CrossRefGoogle Scholar
  12. 12.
    Nieuwenhuizen L, Biesma DH (2010) Central nervous system myelomatosis: review of the literature. Eur J Haematol 80(1):1–9Google Scholar
  13. 13.
    Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, Landmann C, Castelain B, Buijsen J, Curschmann J, Kadish SP, Kowalczyk A, Anacak Y, Hammer J, Nguyen TD, Studer G, Cooper R, Sengoz M, Scandolaro L, Zouhair A (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64(1):210–217. CrossRefGoogle Scholar
  14. 14.
    Schwartz TH, Rhiew R, Isaacson SR, Orazi A, Bruce JN (2001) Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study. Neurosurgery 49(5):1039–1044. (discussion 1044–1035).Google Scholar
  15. 15.
    Liu ZY, Qi XQ, Wu XJ, Luo C, Lu YC (2010) Solitary intracranial plasmacytoma located in the spheno-clival region mimicking chordoma: a case report. J Int Med Res 38(5):1868–1875. CrossRefGoogle Scholar
  16. 16.
    Na’ara S, Amit M, Gil Z, Billan S (2016) Plasmacytoma of the skull base: a meta-analysis. J Neurol Surg Part B 77(1):61–65. CrossRefGoogle Scholar
  17. 17.
    Ferreira-Filho LA, Pedroso JL, Sato EA, Yared JH, Barsottini OG, Bulle Oliveira AS, Diniz-Ferreira NP (2014) Teaching neuroimages: “mini brain” sign: a radiologic marker for vertebral solitary plasmacytoma. Neurology 82(23):e210–e211. CrossRefGoogle Scholar
  18. 18.
    Provenzale JM, Schaefer P, Traweek ST, Ferry J, Moore JO, Friedman AH, McLendon RE (1997) Craniocerebral plasmacytoma: MR features. AJNR Am J Neuroradiol 18(2):389–392Google Scholar
  19. 19.
    Cerase A, Tarantino A, Gozzetti A, Muccio CF, Gennari P, Monti L, Di Blasi A, Venturi C (2008) Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology 50(8):665–674. CrossRefGoogle Scholar
  20. 20.
    Juneau P, Schoene WC, Black P (1992) Malignant tumors in the pituitary gland. Arch Neurol 49(5):555–558. CrossRefGoogle Scholar
  21. 21.
    Devoe CE, Li JY, Demopoulos AM (2014) The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide. J Neuro-oncol 119(1):217–220. CrossRefGoogle Scholar
  22. 22.
    Krause S, Hillengass J, Goldschmidt H, Debus J, Neuhof D (2011) Radiotherapy of solitary plasmacytoma. Ann Hematol 90(9):1093–1097. CrossRefGoogle Scholar
  23. 23.
    Finsinger P, Grammatico S, Chisini M, Piciocchi A, Foa R, Petrucci MT (2016) Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol 172(4):554–560. CrossRefGoogle Scholar
  24. 24.
    Corwin J, Lindberg RD (1979) Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer 43(3):1007–1013CrossRefGoogle Scholar
  25. 25.
    Vengalathur RG, Kavindapadi KV, Chandramouli B (2014) Primary plasmacytoma of the anterior skull base: a rare case. Neurology India 62(5):545–546. CrossRefGoogle Scholar
  26. 26.
    Rahman EZ, Barros Palau AE, Morgan ML, Lee AG (2016) Neuro-ophthalmic presentations of clival plasmacytoma. Can J Ophthalmol 51(2):e49–e53. CrossRefGoogle Scholar
  27. 27.
    Chim CS, Ooi GC (2005) Bulbar palsy in multiple myeloma. Haematologica 90(12 Suppl):ECR42Google Scholar
  28. 28.
    Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992) Plasmacytoma. Treatment results and conversion to myeloma. Cancer 69 (6):1513–1517.;2-X CrossRefGoogle Scholar
  29. 29.
    Mancilla-Jimenez R, Tavassoli FA (1976) Solitary meningeal plasmacytoma: report of a case with electron microscopic and immunohistologic observations. Cancer 38(2):798–806CrossRefGoogle Scholar
  30. 30.
    Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-Maqueo JC (1996) Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 14 (3):111–117.;2-G CrossRefGoogle Scholar
  31. 31.
    Vujovic O, Fisher BJ, Munoz DG (1998) Solitary intracranial plasmacytoma: case report and review of management. J Neuro-oncol 39(1):47–50. CrossRefGoogle Scholar
  32. 32.
    Ferrari S, Tecchio C, Turri G, Richelli S, Ghimenton C, Monaco S, Todeschini G (2012) Unusual case of solitary intraparenchymal brain plasmacytoma. J Clin Oncol 30(33):e350–e352. CrossRefGoogle Scholar
  33. 33.
    Krumholz A, Weiss HD, Jiji VH, Bakal D, Kirsh MB (1982) Solitary intracranial plasmacytoma: two patients with extended follow-up. Ann Neurol 11(5):529–532. CrossRefGoogle Scholar
  34. 34.
    Mussetti A, Dalto S, Montefusco V (2013) Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma 54(4):864–866. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019
corrected publication January 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Beijing Tiantan HospitalCapital Medical UniversityBeijingPeople’s Republic of China

Personalised recommendations